Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

966
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
966
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

963
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
963
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.8K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.8K
Accuracy and Errors in Hypothesis Testing01:13

Accuracy and Errors in Hypothesis Testing

693
Hypothesis testing is a fundamental statistical tool that begins with the assumption that the null hypothesis H0 is true. During this process, two types of errors can occur: Type I and Type II. A Type I error refers to the incorrect rejection of a true null hypothesis, while a Type II error involves the failure to reject a false null hypothesis.
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
693
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing Automated Lyumjev® Delivery with Carbohydrate Counting, Qualitative Meal-Size Estimation, and Fully Closed-Loop in Type 1 Diabetes: A Pilot, Randomized, Crossover Trial.

Diabetes technology & therapeutics·2026
Same author

Design and Evaluation of a Novel Clinical Decision Support Algorithm for Weekly Insulin Efsitora Alfa.

Journal of diabetes science and technology·2026
Same author

The Virtual Diabetes Control and Complications Trial #4: Relationship of HbA1c and Continuous Glucose Monitoring Metrics with Severe Hypoglycemic Events.

Diabetes technology & therapeutics·2026
Same author

Evaluating pain and neurological function with high frequency 10 kHz spinal cord stimulation in the treatment of painful diabetic neuropathy: design of a multicentre, randomised controlled trial (PDN-Sensory).

BMJ open·2025
Same author

The Virtual DCCT #3: Relationship of HbA1c and CGM Metrics with Cardiovascular Outcomes.

Diabetes technology & therapeutics·2025
Same author

Continuous glucose monitoring versus fasting blood glucose basal insulin titration: a retrospective analysis.

Diabetes & metabolic syndrome·2025

Related Experiment Video

Updated: Apr 7, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor.

Daniel A Finan1, Eyal Dassau2, Marc D Breton3

  • 1Animas Corporation, Chesterbrook, PA, USA dfinan@its.jnj.com.

Journal of Diabetes Science and Technology
|July 3, 2015
PubMed
Summary

The Hypo Minimizer system effectively prevents hypoglycemia by adjusting insulin delivery based on continuous glucose monitoring. The most aggressive setting provided the best glucose control without adverse events.

Keywords:
Aggressiveness factoralgorithmartificial pancreasclosed-loop controlmodel predictive controltype 1 diabetes

More Related Videos

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.6K
Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.6K
Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K

Area of Science:

  • Endocrinology
  • Biomedical Engineering
  • Diabetes Technology

Background:

  • The Predictive Hypoglycemia Minimizer System (Hypo Minimizer) uses a predictive controller and safety module to reduce hypoglycemia.
  • Continuous glucose monitor (CGM) data informs insulin delivery adjustments.
  • The "aggressiveness factor" controls the system's response to glucose changes.

Purpose of the Study:

  • To evaluate the impact of the aggressiveness factor on the Hypo Minimizer's automated insulin delivery.
  • To assess the effect of different aggressiveness settings on glucose control outcomes in type 1 diabetes.

Main Methods:

  • Twelve adults with type 1 diabetes participated in a 24-hour closed-loop study.
  • The study analyzed the controller's insulin dosing recommendations at varying aggressiveness levels.
  • Glucose control metrics were compared across different settings.

Main Results:

  • Increased aggressiveness led to reduced insulin recommendations during critical glucose decline periods.
  • The most aggressive setting minimized time spent below 70 mg/dl and maximized time between 70-180 mg/dl.
  • No hyperglycemia, diabetic ketoacidosis, or severe hypoglycemia occurred across all settings.

Conclusions:

  • The Hypo Minimizer controller effectively predicted and preempted hypoglycemia.
  • The highest aggressiveness setting demonstrated the fastest response to reduce insulin delivery and yielded optimal glucose control.